Value and cancer medicines—A personal view

详细信息    查看全文

• 作者：Kenneth R Paterson ^{ken.paterson@dsl.pipex.com}
• 关键词：Cancer medicines ; Clinical value ; Cost-effectiveness ; Health technology assessment ; Reimbursement decision-making ; Health economics
• 刊名：Journal of Cancer Policy
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：11
• 期：Complete
• 页码：26-31
• 全文大小：249 K
• 卷排序：11

文摘

The incremental clinical benefit over existing therapy represents relevant clinical value. While new oncology medicines did offer health benefits over existing therapies, the benefits were generally quite modest. Cost-effectiveness considerations often played a role in non-acceptance decisions, but other factors influenced the decision as well. Price discounting, payment by results and similar schemes aim to share the risk that the clinical value is not as great as is described.